Eisai Inc. Announces Retirement of President and CEO
Company Appoints New Executive Leaders

WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years. Over the next few months, these executives will work closely to ensure a seamless management transition.  

In his role as chairman and CEO, Mr. Matsue will be responsible for the strategic direction of the Americas Region. Ms. Procida, as president and COO, will have full operating responsibility for the U.S. business. Together they also will provide regional management support and oversight to all of Eisai's operating companies and units in the Americas.

"Yuji and Shaji bring significant industry experience and expertise to their new roles within Eisai," said Haruo Naito, president and CEO of Eisai Co., Ltd. "Their leadership will be instrumental in taking Eisai to the next level as we work to broaden access to many of Eisai's products across the Americas Region and advance our human health care mission."   

"We are grateful to Lonnel Coats for the outstanding leadership he has displayed during his 18-year tenure with Eisai," added Mr. Naito. "He has played an integral role in shaping Eisai's business strategy and operations, positioning us for continued success. On behalf of everyone at Eisai, I express my deep appreciation to Lonnel for his many contributions." 

"I thank Mr. Naito for the privilege of leading Eisai's Americas business and advancing our company's human health care mission to serve patients and their families," said Lonnel Coats. "After ten years at the helm of Eisai Inc., I am immensely proud to turn over the leadership of our business to my colleagues, Yuji Matsue and Shaji Procida. They are highly skilled executives with deep knowledge of our company, our products and our partners, and are dedicated to our patient-centered approach to running our business."

Mr. Matsue joined Eisai in 1982 and has had a long and successful career with the company, holding a number of leadership positions in Japan, Europe and the United States. Most recently, he has served as deputy president of the Asia region at Eisai Co., Ltd. Early in his career, in 1995, Mr. Matsue came to the United States to become one of the first five employees of Eisai Inc. At that time, he served as one of the key leaders for the U.S. launch of Aricept® (donepezil hydrochloride), which was Eisai's first pharmaceutical product in the United States. During his tenure, Mr. Matsue attained roles of increasing responsibility, culminating in his 2001 appointment as vice president of commercial development where he led all corporate planning and business development activities in the United States.

In 2006, Mr. Matsue was promoted to senior vice president of planning and strategy at Eisai Europe Ltd. in London. There he held several leadership positions within project management and also played a key role in the global expansion of Eisai's European operation. Three years later, Mr. Matsue returned to Tokyo to accept the position of vice president of global public relations and investor relations. During this time, he also was appointed a corporate officer of Eisai Co., Ltd. Shortly thereafter, in 2011, Mr. Matsue was named vice president of talent management within Eisai's Talent Innovation Headquarters. He assumed the position of president of the Indo-Pacific region in 2012 and deputy president of the Asia region in 2013.

Mr. Matsue holds a BA in economics from Keio University in Japan and an MBA from the Fuqua School of Business at Duke University in the United States. 

Ms. Procida joined Eisai Inc. in 1998 as manager of financial consolidations and reporting. Over the years, she has held positions of increasing responsibility within finance and accounting. In 2005, Ms. Procida was appointed the key leadership role of controller, where she led the accounting, financial reporting, budgeting and consolidation functions. In 2010, she was promoted to vice president of finance, ascending to chief financial officer in 2012.   

Ms. Procida holds a BA in accounting from Pace University. She also is a member of the Financial Executive Institute and the Healthcare Businesswomen's Association (HBA). In 2006, Ms. Procida was recognized as a Rising Star by the HBA at its annual Woman of the Year event. 

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products across the world through a global network of research facilities, manufacturing sites and marketing subsidiaries. For more information about Eisai's global operations, please visit www.eisai.com.

Media Inquiries                          

Investor Inquiries

Suzanne Grogan

Alex Scott

Eisai Inc.

Eisai Inc.




SOURCE Eisai Inc.

Type Press Release

Date Released March 10, 2014

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields